Table 3.

Univariate Cox regression of the 24 clinical and blood-based biomarkers according to the primary endpoint of time to progression

Factors	β	Wald	HR	95% CI	p value
Gender	0.20	0.35	1.22	0.63–2.34	0.56
Age	− 0.02	0.004	0.98	0.58–1.73	0.95
EOCG	0.11	0.05	1.11	0.45–2.73	0.82
Number of smoke	− 0.25	1.01	0.78	0.47–1.27	0.31
Smoke status	0.12	0.13	1.13	0.60–2.11	0.72
History of lung cancer	0.16	0.35	1.17	0.70–1.95	0.55
Family history	0.92	3.57	2.50	0.97–6.45	0.06
WBC	0.35	1.40	1.42	0.79–2.55	0.24
NE	− 0.02	0.003	0.98	0.56–1.72	0.95
LY	− 0.26	0.66	0.77	0.42–1.44	0.42
MONO	− 0.19	0.57	0.83	0.51–1.35	0.45
EO	0.21	0.29	1.23	0.58–2.59	0.59
HB	0.0001	0.001	1.00	0.56–1.79	0.99
PLT	0.32	0.79	1.38	0.68–2.82	0.37
ALT	0.73	3.98	2.08	1.01–4.26	0.03*
TBIL	− 0.46	0.59	0.63	0.20–2.04	0.44
ALB	− 0.05	0.02	0.95	0.49–1.85	0.89
AST	1.17	13.14	3.22	1.71–6.04	< 0.0001*
FG	0.11	0.120	1.11	0.60–2.06	0.73
TP	− 0.22	0.67	0.81	0.48–1.35	0.41
CEA	0.76	6.21	2.13	1.18–3.85	0.01*
T stage	− 0.01	0.002	0.99	0.56–1.74	0.96
N stage	0.26	0.53	1.30	0.64–2.65	0.47
M stage	0.02	0.007	1.02	0.63–1.67	0.93

The median of the number of smoke (9600 cigarettes) was used as the cut-off value. TNM stage was divided into three variables for analysis

WBC white blood cell, NE neutrophil, LY lymphocyte, MONO monocytes, EO eosinophils, HB hemoglobin, PLT platelet, ALT alanine aminotransferase, TBIL total bilirubin, ALB albumin, AST aspartate aminotransferase, FG fibrinogen, TP total protein, CEA carcinoembryonic antigen

*The factor is significantly associated with time to progression